- CytoDyn Announces FDA Has Lifted Clinical Hold
- CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
- CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
- CytoDyn Announces Webcast to Provide Company Update
- CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
- November 2023 Letter to Shareholders
- CytoDyn Announces Company Updates and Investment Community Update Webcast
More ▼
Key statistics
On Wednesday, Cytodyn Inc (CYDY:QBB) closed at 0.1485, 16.47% above the 52 week low of 0.1275 set on Apr 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.150 |
---|---|
High | 0.1539 |
Low | 0.145 |
Bid | -- |
Offer | -- |
Previous close | 0.150 |
Average volume | 1.22m |
---|---|
Shares outstanding | 993.37m |
Free float | 985.39m |
P/E (TTM) | -- |
Market cap | 149.00m USD |
EPS (TTM) | -0.055 USD |
Data delayed at least 15 minutes, as of Apr 24 2024 20:55 BST.
More ▼